Jung-Sun Park

Jung-Sun Park

Auto-generated profile, based on publicly available information

Jung-Sun Park

Data Labs, SK Telecom, Seoul 04539, Korea

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
YSYOUNG SHIN SONG
YOUNG SHIN SONG
BKByung-Hee Kang
Byung-Hee Kang
SLSeungbok Lee
Seungbok Lee
SYSeong-Keun Yoo
Seong-Keun Yoo
YCYoung Sik Choi
Young Sik Choi
YPYoung Joo Park
Young Joo Park
It is controversial as to whether papillary thyroid microcarcinoma (PTMC) has some genomic and transcriptomic characteristics that differentiate between an early-stage lesion that would eventually evolve into the larger papillary thyroid cancer (PTC), and an occult indolent cancer in itself. To investigate this, we comprehensively elucidated the genomic and transcriptomic landscapes of PTMCs of different sizes, using a large-scaled database. This study included 3435 PTCs, 1985 of which were PTMCs. We performed targeted next-generation sequencing for 221 PTCs and integrated these data with the data including The Cancer Genome Atlas (TCGA) project. The frequency of v-raf murine sarcoma viral oncogene homolog B (BRAF)V600E mutation was higher in PTMCs >0.5 cm than that in very small PTMCs (≤0.5 cm) and decreased again in PTCs >2 cm. Among PTMCs, the prevalence of mutations in rat sarcoma (RAS) and telomerase reverse transcriptase (TERT) promoter was not significantly different according to their size, but lower than in large PTCs. There was no change in the tumor mutational burden, the number of driver mutations, and transcriptomic profiles with tumor size, among PTMCs and all PTCs. Although a few genes with differential expression and TERT promoter mutations were found in a few PTMCs, our findings showed that there were no useful genomic or transcriptomic characteristics for the prediction of the future progression of PTMC.

1 January 2019 in Journal of Korean Medical Science
Verified
Journal Article
Open access
DLDa Eun Lee
Da Eun Lee
HKHyunjin Kim
Hyunjin Kim
JPJungsun Park
Jungsun Park
TYTaegyun Yun
Taegyun Yun
DPDong Yoon Park
Dong Yoon Park
HRHyun Mee Ryu
Hyun Mee Ryu
Lee DE, et al. J Korean Med Sci. 2019 Jun;34(24):e172. https://doi.org/10.3346/jkms.2019.34.e172

3 August 2021
Verified
Book Chapter
Closed access
JPJung-Sun Park
Jung-Sun Park
7. Trans-Pacific Flows and US Audiences of Korean Popular Culture was published in Global East Asia on page 91.

16 November 2005 in Blood
Verified
Journal Article
Open access
HKHyun-Kyu Kang
Hyun-Kyu Kang
JPJung-Sun Park
Jung-Sun Park
BCBo-Hwa Choi
Bo-Hwa Choi
TNThanh-Nhan Nguyen
Thanh-Nhan Nguyen
XZXiao-Wei Zhu
Xiao-Wei Zhu
JLJe-Jung Lee
Je-Jung Lee
Vascular endothelial growth factor (VEGF), produced by most tumors, not only plays an important role in tumor angiogenesis but also can inhibit the maturation of dendritic cells (DCs) from hematopoietic progenitors. In this study, we investigated the relationship between the clinical characteristics of patients with acute myeloid leukemia (AML) and the generation of DCs from the leukemic cells, and found that cellular VEGF level in leukemic cells affected the generation of leukemic-DCs in vitro. Leukemic-DCs were successfully generated from 16 of 21 AML patients, and generated leukemic DCs exhibited high level of HLA-DR and CD54 expression, and intermediate level of CD80, CD86, CD83, and CD1a expression. Leukemic-DCs also were able to stimulate allogeneic T cell proliferation and cytotoxic activities against autologous leukemic cells. The failure of generation of leukemic-DCs from leukemic cells in some AML patients was related with its cellular VEGF levels. The leukemic cells that failed to generate leukemic-DCs had significantly higher cellular VEGF levels than that of generated leukimic-DCs (p = 0.005), and neutralizing of VEGF with anti-VEGF Ab inhibited the cellular VEGF level at the transcription level as determined by RT-PCR analysis, and at the protein level determined by West blotting and ELISA. Inhibition of cellular VEGF levels induced the generation of leukemic-DCs determined by increased levels of surface markers, namely, CD40, CD80, CD86, and HLA-DR. Moreover, inhibition of cellular VEGF levels also increased IL-12 production and allosimulatory capacity of leukemic-DCs, suggesting functional differentiation of leukemic-DCs. Interestingly, cellular VEGF levels also are inversely related to the achievement of complete remission for induction therapy (p = 0.02). Taken together, these results suggest that cellular VEGF levels during the differentiation of AML cells to leukemic-DCs are a predictive marker of the positive response of the AML patients to the remission-inducing therapy, and down-regulation of cellular VEGF levels can be one target of cancer immunotherapy by generating of sufficient number of DCs in AML patients.